LATIGO BIOTHERAPEUTICS
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependence or tolerability.
LATIGO BIOTHERAPEUTICS
Founded:
2018-01-01
Total Employee:
1+
Status:
Active
Total Funding:
15 M USD
Similar Organizations
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Teligene
Teligene is a drug discovery company edicating to developing innovative small-molecule drugs.
Current Employees Featured
Investors List
Corner Ventures
Corner Ventures investment in Funding Round - Latigo Biotherapeutics
More informations about "Latigo Biotherapeutics"
home - Latigo Biotherapeutics
We are a clinical-stage company developing innovative non-opioid pain medicines with best-in-class profiles. Reducing pain lowers stress and facilitates healing. There is a large unmet need …See details»
Latigo Biotherapeutics - Crunchbase Company Profile …
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood …See details»
Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead …
Aug 19, 2024 · Latigo Biotherapeutics is a private clinical-stage biotechnology company developing innovative non-opioid pain medicines with potential best-in-class profiles that …See details»
Latigo Biotherapeutics, Inc. | LinkedIn
Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the...See details»
Latigo Biotherapeutics Debuts with $135 Million Series A …
Feb 14, 2024 · THOUSAND OAKS, Calif., February 14, 2024 – Latigo Biotherapeutics Inc. (“Latigo”), a clinical-stage biotechnology company developing best-in-class non-opioid pain …See details»
Amgen vets launch Latigo Biotherapeutics to develop …
Feb 14, 2024 · Latigo Biotherapeutics is launching after 4-plus years in stealth. The California biotech will develop pain drugs that could one day replace opioids. Venture capital firm Westlake Village BioPartners, based just northwest of Los …See details»
Latigo Biotherapeutics Debuts with $135 Million Series …
THOUSAND OAKS, Calif., Feb. 14, 2024 /PRNewswire/ -- Latigo Biotherapeutics Inc. ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target...See details»
Latigo Biotherapeutics Debuts with $135 Million Series …
Feb 15, 2024 · Latigo Biotherapeutics Inc. ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today announced its emergence from stealth with a …See details»
Latigo Biotherapeutics - VentureRadar
Latigo Biotherapeutics is a biotech company focused on developing innovative non-opioid medicines for pain relief. The firm leverages human biology to create new classes of pain …See details»
science - Latigo Biotherapeutics
We start with sophisticated models, human biological insights, and a discovery engine that sets us apart, offering best-in-class potential. We have multiple novel pain programs in discovery and development that leverage our internal ion …See details»
CRO Lotus' founder leaps to Latigo - Fierce Biotech
Aug 20, 2024 · Pain-medicine-focused Latigo Biotherapeutics is welcoming CRO founder Neil Singla, M.D., aboard as chief medical officer. Back in 2001, Singla formed Lotus Clinical …See details»
Latigo Launches into Non-Opioid Pain Medicine Space with $135 …
Feb 13, 2024 · Founded by Westlake Village BioPartners in 2020, Latigo is developing non-opioid-based therapeutics against genetically validated targets for pain—and with the opioid …See details»
Latigo Biotherapeutics Announces Positive Phase 1 Data for
Aug 19, 2024 · Latigo Biotherapeutics is a private clinical-stage biotechnology company developing innovative non-opioid pain medicines with potential best-in-class profiles that …See details»
Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead …
Aug 19, 2024 · Latigo Biotherapeutics Inc. ("Latigo") today announced positive Phase 1 results for LTG-001, its lead potential best-in-class non-opioid pain medicine candidate.See details»
Hunting a non-opioid painkiller, a biotech reveals plans to chase ...
Feb 14, 2024 · Latigo Biotherapeutics has raised $135 million to develop drugs that block NaV1.8, the target of a Vertex therapy that just succeeded in Phase 3 trials.See details»
Nima Farzan, MBA - Latigo Biotherapeutics
Nima serves as the Chief Executive Officer at Latigo Biotherapeutics, bringing more than two decades of leadership experience in the biopharmaceutical industry. Known for his strong …See details»
Latigo raises $135M to catch up to Vertex in chronic pain - Fierce …
Feb 14, 2024 · Latigo broke stealth cover today with $135 million to chase Vertex, the front runner in the effort to develop a new non-opioid pain option. Latigo Biotherapeutics unveiled …See details»
Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead …
Aug 19, 2024 · Latigo Biotherapeutics is a private clinical-stage biotechnology company developing innovative non-opioid pain medicines with potential best-in-class profiles that …See details»
Latigo launches with $135 million for Vertex-competing pain drug
Feb 14, 2024 · The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed …See details»